R&D Efficiency Evaluation And Its Influencing Factors Of Chinese Pharmaceutical Manufacturing Based On StoNED

Pharmaceutical manufacturing industry is an important and sunrise industry that related to national economy and people’s livelihood.Since the reform and opening up,China’s pharmaceutical manufacturing industry has maintained a relatively fast development speed.With the increasing population aging problem,the increasing urbanization level and the interaction role of medical insurance system,the pharmaceutical manufacturing industry will usher in a new period of rapid development.However,the pharmaceutical industry of "twelfth five-year" development plan pointed out that although the rapid development of Chinese medicine manufacturing enterprise in recent years and is expected to become the second largest pharmaceutical market in the world in 2020,but still there exists prominent contradictions problems of the weak technology innovation ability and low enterprise R&D input in pharmaceutical manufacturing industry.In particular,there are major defects in the R&D of new products for chemical,traditional Chinese medicine and biotechnology drugs.Therefore,how to accelerate the technological progress of the pharmaceutical manufacturing industry,to accecelerate the R&D efficiency,to make our country translate from the pharmaceutical production country into relying on the advantage of R&D innovation power,is an important research subject.Based on the above thinking,this article uses the related research at home and abroad for reference,combined with the characteristics of pharmaceutical manufacturing R&D,using StoNED model--fusion model of DEA model and SFA model to evaluate the R&D efficiency in our country of medical manufacturing industry from 2009 to 2015.On this basis,the method of econometrics is used to analyze the influenced factors on R&D efficiency in China’s pharmaceutical manufacturing industry.Finally,according to the conclusions of the empirical analysis,combining with the existing problems in China’s pharmaceutical manufacturing industry,it puts forward some targeted improvement measures.The research results of this paper are mainly reflected in the following aspects:1.Analyzed of the R&D input and output of pharmaceutical industry in China.The research shows that from 2009 to 2015 R&D inputs(R&D personnel and R&D expenses)and output(new product sales revenue and patent applications)presents the increasing trend year by year,and shows significant regional differences.2.The overall R&D efficiency of pharmaceutical industry in China shows a trend of fluctuating growth.Overall,the R&D efficiency of China’s pharmaceutical manufacturing industry is increasing,but the fluctuation range is different.3.The R&D efficiency of pharmaceutical industry in China has obvious regional characteristics.From the perspective of large regions,the R&D efficiency of the provinces in north China,central China and southern China is relatively high,while the efficiency values in the western regions and the northeast region are low.4.Analysis of pharmaceutical manufacturing R&D efficiency with internal and external affecting factors.The result shows that in the internal factors,input factors(mainly refers to the investment of R&D capital and R&D personnel proportion)of pharmaceutical manufacturing industry can positive promote the efficiency of R&D significantly;In the non-input internal factors,the growth capacity of the industry and the willingness of R&D can effectively improve the efficiency of R&D.Based on the above analysis,the following suggestions are put forward:(1)for companies,especially large pharmaceutical companies,should actively participate in the investment in R&D activities and the input of R&D(R&D funds and R&D personnel).For small businesses,they should positive participate and seek for diversified approach to R&D.(2)for the government,local governments should actively develop the regional economy,actively introduce and encourage the development of high-tech industries;In addition,relevant government departments should introduce relevant policies to encourage enterprises to actively participate in R&D.More importantly,the government should increase funding for R&D.